Stockreport
Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits [Yahoo! Finance]
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations: ir.edwards.com
NEW ORLEANS, March 30, 2026 BUSINESS WIRE )--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during a late-breaking featured research session at ACC.26 demonstrated confidence in two-year performance of TTVR with the EVOQUE system and showed: Significant and sustained near elimination of tricuspid regurgitation (TR); Improvements in health status and quality of life; No added device-related risk; and Significantly lower all-cause mortality when accounting for patient crossover. "There is a significant patient population suffering with debilitating symptoms from tric
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EW | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EW alerts
EW alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
NEWS
NEWS
- Marie O'Malley to Speak on Manufacturing Tradeoffs Panel at MPP West 2026[PR Web]
- A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market [Yahoo! Finance][Yahoo! Finance]
- Edwards Lifesciences (EW) was upgraded by Wolfe Research from "peer perform" to "outperform". They now have a $92.00 price target on the stock.[MarketBeat]
- Boston Scientific: From Hypergrowth To Durable Compounding [Seeking Alpha][Seeking Alpha]
- Philips Wins FDA 510(k) Clearance for AI Heart Valve Repair Solution [Yahoo! Finance][Yahoo! Finance]
- More
EW
SEC Filings
SEC Filings
- 4/2/26 - Form 4
- 3/26/26 - Form SCHEDULE
- 3/26/26 - Form ARS
- EW's page on the SEC website
- More